At a Glance

  • Mature biotech companies in Massachusetts captured the vast majority of private and public investment in 2026, according to an industry report released Tuesday by MassBio, the state's biopharmaceutical trade association.
  • Massachusetts-based pharmaceutical companies raised nearly $3.5 billion in venture capital in the first half of 2026, a 25% increase from the same period in 2025, the report said. Between January and July, eight Boston-area biotech companies completed initial public offerings, with Parabilis Medicines breaking the industry's IPO fundraising record.
  • But MassBio also noted that the data reflects a widening funding gap among startups: the average seed round fell to $4.65 million, while the average Series A round surged to nearly $80 million. The organization also highlighted the rapid rise of China's biotech ecosystem, finding that China's drug pipeline grew 36.2% year-over-year, surpassing Europe for the first time. In contrast, the U.S. drug pipeline remained nearly flat, while Massachusetts grew 9.2%.

In-Depth Analysis

The biotech industry has recovered significantly since bottoming out in 2022. However, despite record IPOs, a rebound in venture capital, and a sharp rise in the XBI exchange-traded fund, many young companies remain left out.

Overall, the industry's top investors have shifted their focus to more mature drug programs that can be advanced quickly. They have become more cautious about participating in seed rounds, leading MassBio to warn in its report that its "biggest concern" is "early-stage startups with the highest scientific risk."

To secure such venture capital backing, founders must demonstrate "novelty, commercial viability, and confidence in leadership," Ben Bradford, MassBio's head of external affairs, said in an interview.

"Importantly, a healthy ecosystem needs this recovery to also reach the front end of the pipeline, where new companies are born and the next generation of promising science is nurtured," Kendalle Burlin O'Connell, MassBio's president and CEO, said in a statement.

The ecosystem may also need new tools to better compete with China. In recent years, licensing deals with Chinese biotech companies have surged, reshaping the global pharmaceutical pipeline and putting pressure on young U.S. companies.

MassBio's inclusion of a "China Watch" section in its report for the first time this year reflects this shift. The section tallies that licensing deals related to drugs discovered in China generated $79 billion in total proceeds last year, compared to just $1 billion in 2019. China is also currently conducting more early-stage clinical trials than any other region analyzed in the report.

"We are far from losing, but while our competitors are sprinting, we are merely treading water," Burlin O'Connell said in the report.

This issue has divided the industry. Some argue for restricting deals, while others believe regulation could do more harm than good. Legislation is still in its early stages, and efforts to include biotech in the COINS Act—to strengthen scrutiny of these collaborations—have not yet become law. Plans to accelerate U.S. drug research also remain in the planning phase.

MassBio has expressed support for such plans. Bradford said many industry players turn to China for licensing, clinical trials, and manufacturing not merely for cost reasons, but for speed.

"When the FDA was created, innovation happened inside large pharmaceutical companies. But that's no longer the case," he said. "Innovation happens in small biotech companies that don't have large regulatory teams or budgets to interpret ambiguous information, and they have to compete with big pharma for the FDA's attention."